Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB

Background An accumulation of somatic mutations in tumors leads to increased neoantigen levels and antitumor immune response. Tumor mutational burden (TMB) reflects the rate of somatic mutations in the tumor genome, as determined from tumor tissue (tTMB) or blood (bTMB). While high tTMB is a biomark...

Full description

Bibliographic Details
Main Authors: Jie He, David Fabrizio, Jonathan Baden, Parul Doshi, James Pratt, Lee A Albacker, Geoffrey R Oxnard, Gina Fusaro, Natallia Kalinava, Dean C Pavlick, Ericka M Ebot, Hanna Tukachinsky, George Green
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/11/e007339.full

Internet

https://jitc.bmj.com/content/11/11/e007339.full

Similar Items